[{"id":"b7d5c857-2d6d-49ee-a382-780def97434a","acronym":"SOHO-01","url":"https://clinicaltrials.gov/study/NCT05099172","created_at":"2021-10-29T14:53:14.073Z","updated_at":"2025-02-25T15:35:22.229Z","phase":"Phase 1/2","brief_title":"First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)","source_id_and_acronym":"NCT05099172 - SOHO-01","lead_sponsor":"Bayer","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hyrnuo (sevabertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-11"},{"id":"4e3eec72-a814-4c0e-9cb1-d5be450dc993","acronym":"BEAMION-Lung 1","url":"https://clinicaltrials.gov/study/NCT04886804","created_at":"2021-05-14T12:52:37.162Z","updated_at":"2025-02-25T15:35:04.451Z","phase":"Phase 1","brief_title":"Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)","source_id_and_acronym":"NCT04886804 - BEAMION-Lung 1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NRG1","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hernexeos (zongertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 554","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-10"},{"id":"1e5fae6d-b76f-41f6-b24b-b33b5b08e9ca","acronym":"ORIC-114-01","url":"https://clinicaltrials.gov/study/NCT05315700","created_at":"2022-04-07T13:56:31.880Z","updated_at":"2024-07-02T16:35:04.393Z","phase":"Phase 1/2","brief_title":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","source_id_and_acronym":"NCT05315700 - ORIC-114-01","lead_sponsor":"ORIC Pharmaceuticals","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • enozertinib (ORIC-114)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-05-10"},{"id":"852151a9-cba1-4072-ae4f-f77c8a4d1517","acronym":"FWD1509","url":"https://clinicaltrials.gov/study/NCT05068024","created_at":"2021-10-05T20:00:15.364Z","updated_at":"2024-07-02T16:36:06.718Z","phase":"Phase 1/2","brief_title":"A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05068024 - FWD1509","lead_sponsor":"Forward Pharmaceuticals Co., Ltd.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • HER-2 A775","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • HER-2 A775"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FWD1509"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 10/30/2022","primary_completion_date":" 10/30/2022","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2022-07-26"},{"id":"1ba66b3e-54fe-4d02-972d-169ab5065f83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05435274","created_at":"2022-06-28T15:54:10.303Z","updated_at":"2024-07-02T16:36:08.178Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05435274","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS-10376"],"overall_status":"Recruiting","enrollment":" Enrollment 380","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 10/07/2024","primary_completion_date":" 10/07/2024","study_txt":" Completion: 10/07/2025","study_completion_date":" 10/07/2025","last_update_posted":"2022-06-28"}]